Literature DB >> 32524027

REDUCTION IN SUBCUTANEOUS INSULIN REQUIREMENTS IN TETRAPLEGIC TYPE 1 DIABETIC WITH CERVICAL SPINAL CORD INJURY FOLLOWING PRAMLINTIDE TREATMENT.

Frank Salamone, Brian A Berelowitz.   

Abstract

OBJECTIVE: To report a massive increase in subcutaneous insulin requirements following spinal cord injury in a type 1 diabetic and how it was managed over a 22-month period with pramlintide.
METHODS: A case report and brief literature review is presented.
RESULTS: The patient is a 43-year-old male who was diagnosed with type 1 diabetes mellitus at age 18. He remained relatively well-controlled without end-organ complications until age 37, when he developed a spinal epidural abscess following a methicillin-resistant Staphylococcus aureus cellulitis of the foot. The patient became ventilator-dependent and tetraplegic. He remained in rehabilitation for 18 months and returned home with a total daily dose of subcutaneous insulin of 600 U (4 U/kg); a 500 U increase over his prespinal cord injury requirements. Total daily intravenous insulin requirement was determined to be 259 U (1.96 U/kg). The patient was started on pramlintide. Twenty-two months after the onset of pramlintide treatment his total daily dose of subcutaneous insulin was decreased to 150 U (1.3 U/kg).
CONCLUSION: Maintenance of glycemic control and obesity in type 1 diabetics with spinal cord injury may be complicated by autonomic dysregulation and the inability to induce activity-related lifestyle changes. Our patient exhibited clinical evidence of impaired subcutaneous insulin absorption that was not ameliorated by site changes, leading to massive insulin requirements which greatly reduced his quality of life. Following treatment with pramlintide, he decreased the volume of his insulin injections and lost 19 kg (41 pounds). Uncovering the precise mechanisms by which pramlintide benefited our patient requires further studies.
Copyright © 2020 AACE.

Entities:  

Year:  2020        PMID: 32524027      PMCID: PMC7282281          DOI: 10.4158/ACCR-2019-0461

Source DB:  PubMed          Journal:  AACE Clin Case Rep        ISSN: 2376-0605


  8 in total

1.  Study reanalysis using a mechanism-based pharmacokinetic/pharmacodynamic model of pramlintide in subjects with type 1 diabetes.

Authors:  Jing Fang; Cornelia B Landersdorfer; Brenda Cirincione; William J Jusko
Journal:  AAPS J       Date:  2012-10-02       Impact factor: 4.009

Review 2.  Effects of spinal cord injury on body composition and metabolic profile - part I.

Authors:  Ashraf S Gorgey; David R Dolbow; James D Dolbow; Refka K Khalil; Camilo Castillo; David R Gater
Journal:  J Spinal Cord Med       Date:  2014-07-07       Impact factor: 1.985

Review 3.  Amylin: Pharmacology, Physiology, and Clinical Potential.

Authors:  Debbie L Hay; Steve Chen; Thomas A Lutz; David G Parkes; Jonathan D Roth
Journal:  Pharmacol Rev       Date:  2015-07       Impact factor: 25.468

Review 4.  Amylin activates distributed CNS nuclei to control energy balance.

Authors:  Elizabeth G Mietlicki-Baase; Matthew R Hayes
Journal:  Physiol Behav       Date:  2014-01-28

5.  Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial.

Authors:  R E Ratner; R Dickey; M Fineman; D G Maggs; L Shen; S A Strobel; C Weyer; O G Kolterman
Journal:  Diabet Med       Date:  2004-11       Impact factor: 4.359

Review 6.  Autonomic function following cervical spinal cord injury.

Authors:  Andrei Krassioukov
Journal:  Respir Physiol Neurobiol       Date:  2009-08-12       Impact factor: 1.931

7.  Cutaneous microvascular perfusion responses to insulin iontophoresis are differentially affected by insulin resistance after spinal cord injury.

Authors:  Michael F La Fountaine; Christopher M Cirnigliaro; Frank Azarelo; Joshua C Hobson; Oriana Tascione; Kirsten N Swonger; Trevor Dyson-Hudson; William A Bauman
Journal:  Exp Physiol       Date:  2017-08-08       Impact factor: 2.969

8.  Mechanisms of activity-dependent plasticity in cellular nitric oxide-cGMP signaling.

Authors:  Edward J Halvey; Jeffrey Vernon; Brijesh Roy; John Garthwaite
Journal:  J Biol Chem       Date:  2009-07-15       Impact factor: 5.157

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.